Kite, a Gilead Company, has announced a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology firm, for $350 million. Interius is known for its development of in vivo CAR therapeutics. The acquisition is set to enhance Kite's cell therapy capabilities by integrating Interius's in vivo platform, which allows the generation of CAR T-cells directly within a patient's body. This innovative approach could potentially streamline treatment processes by eliminating the need for cell harvesting and reinfusion associated with traditional therapies. Interius's team will join Kite's research operations, forming a center of excellence in Philadelphia to expedite the development of next-generation in vivo therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.